Skip to content

Psilocybin: all studies

Page 133 of 440: studies 1,321 to 1,330 of 4,400, newest first. Back to the psilocybin overview

Research

Matrix-assisted laser-desorption/ionization-mass spectrometric imaging of psilocybin and its analogues in psychedelic mushrooms using a cesium chloride-coated target plate.

Analytical and Bioanalytical Chemistry December 2, 2022

Fungi with hallucinogenic properties and neurotoxicity have been listed as prohibited drugs in recent years, but there is a lack of in situ quantification of psilocybin and analogues in these samples to avoid the decomposition of these psychoactive tryptamines in time-consuming sample preparation. In this study, matrix-assisted laser-desorption/ionization (MALDI)-Fourier transform ion cyclotron...

Psilocybin-Assisted Psychotherapy in Palliative Care

Oxford University Press eBooks December 1, 2022 Stephen Ross, Anthony P. Bossis

Abstract Following a decades-long hiatus and building on an innovative research model first developed from the 1960s to 1970s utilizing psychedelic therapeutics to alleviate the marked psychic distress in end-of-life cancer patients, major academic centers are resuming contemporary clinical research into the safety and efficacy of psilocybin and other serotonergic psychedelics delivered in...

DOI: 10.1093/med/9780197583838.003.0042 (opens in new tab) Psilocybin Psychotherapist Palliative care Distress +2

Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.

Contemporary Clinical Trials December 1, 2022 Kelley C O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et al. 24 citations

Several lines of evidence suggest that classic psychedelics (5-HT2A receptor agonists or partial agonists) such as psilocybin might facilitate behavior change in individuals with substance use disorders. We conducted a multi-site, double-blind, randomized controlled trial (RCT) to assess the effects of psilocybin-assisted psychotherapy in alcohol-dependent volunteers. In addition to a...

Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields.

3 Biotech December 1, 2022 Dominique Strauss, Soumya Ghosh, Zurika Murray et al. 13 citations

Humans have collected and used hallucinogenic mushrooms for ethnic medicinal, recreational, and religious purposes since before recorded history. Currently, the use of these mushrooms is illegal in most countries, but where their use is legal they are applied as self medication. Psilocybin and psilocin, two psychoactive alkaloids, are naturally synthesized by hallucinogenic mushrooms. The...

Therapeutic use of psilocybin: Practical considerations for dosing and administration

Frontiers in Psychiatry December 1, 2022 Jagpaul Kaur Deol, Caroline A. Maccallum, Lindsay A. Lo et al. 95 citations

The interest in psilocybin as a therapeutic approach has grown exponentially in recent years. Despite increasing access, there remains a lack of practical guidance on the topic for health care professionals. This is particularly concerning given the medical complexity and vulnerable nature of patients for whom psilocybin-assisted psychotherapy may be considered. This article aims to provide...

DOI: 10.3389/fpsyt.2022.1040217 (opens in new tab) Psilocybin Dosing Health professionals Health care +5

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report

Heliyon December 1, 2022 Benjamin Kelmendi, Giuliana DePalmer, Gayle Maloney et al. 34 citations

Classic psychedelics, such as psilocybin, act on the brain's serotonin system and produce striking psychological effects. Early work in the 1950s and 1960s and more recent controlled studies suggest benefit from psychedelic treatment in a number of conditions. A few case reports in recreational users and a single experimental study suggest benefit in patients with obsessive-compulsive disorder...

DOI: 10.1016/j.heliyon.2022.e12135 (opens in new tab) Psilocybin Obsessive compulsive Hallucinogen Psychotherapist

Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression

Journal of Psychopharmacology November 26, 2022 Melissa Shukuroglou, Leor Roseman, David Nutt et al. 38 citations

Background: Music listening is a staple and valued component of psychedelic therapy, and previous work has shown that psychedelics can acutely enhance music-evoked emotion. Aims: The present study sought to examine subjective responses to music before and after psilocybin therapy for treatment-resistant depression, while functional magnetic resonance imaging (fMRI) data was acquired. Methods:...

Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives

Frontiers in Psychology November 17, 2022 Catharina Messell, Lisa Summer, Lars Ole Bonde et al. 22 citations

The psychedelic drug psilocybin has been successfully explored as a novel treatment for a range of psychiatric disorders. Administration of psilocybin requires careful attention to psychological support and the setting in which the drug is administered. The use of music to support the acute psychoactive effects of psilocybin is recommended in current guidelines, but descriptions of how to...

DOI: 10.3389/fpsyg.2022.873455 (opens in new tab) Psilocybin Music therapy Pop music automation Psychological intervention +2

Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications

International Journal of Molecular Sciences November 16, 2022 Orr Shahar, Alexander Botvinnik, Noam Esh-Zuntz et al. 60 citations

There is increasing interest in the therapeutic potential of psilocybin. In rodents, the serotonin precursor, 5-hydroxytryptophan (5-HTP) and psilocybin induce a characteristic 5-HT2A receptor (5-HT2AR)-mediated head twitch response (HTR), which is correlated with the human psychedelic trip. We examined the role of other serotonergic receptors and the trace amine -associated receptor 1 (TAAR1)...

DOI: 10.3390/ijms232214148 (opens in new tab) Full text (opens in new tab) Psilocybin 5-hydroxytryptophan 5-HT Receptor Serotonin antagonists +1

Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine

November 15, 2022 Jeffrey Guss, Robert Krause, Jordan Sloshower preprint

This is the French translation of the Yale Manual for Psilocybin-Assisted Therapy of Depression. Le Manuel de Yale pour le traitement thérapeutique de la dépression assisté par la psilocybine fournit aux chercheurs et aux thérapeutes des méthodes, une structure et des domaines à prendre en compte concernant l'utilisation de la thérapie assistée par les psychédéliques dans le traitement du...